Glumetinib plus chemo for MET-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of a targeted drug (Glumetinib) and chemotherapy (nab-docetaxel) against chemotherapy alone for people with advanced non-small cell lung cancer that has a high level of a protein called MET. It may offer a new option after standard immunotherapy and platinum chemo have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced or metastatic non-small cell lung cancer (stage IIIB, IIIC, or IV) that cannot be surgically removed.
- Your tumor must show high levels of a protein called MET (confirmed by a central lab).
- Your lung cancer must not have common gene changes (like EGFR, ALK, or KRAS mutations) that other drugs target.
- You must have already received both immunotherapy (PD-1/PD-L1 blocker) and platinum chemotherapy (given together or one after the other).
- You must be in fairly good health (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
This trial tests a combination of two drugs, glumetinib and nab-docetaxel, in people with advanced stomach cancer or other solid tumors that have a specific change in the MET gene. The goal is to see if this combination is safe and works better than current treatments.
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
This trial tests a new drug called glumetinib combined with osimertinib for people with advanced non-small cell lung cancer. It may help if the cancer has not been treated with EGFR or MET inhibitors before.
This trial studies savolitinib (an oral MET-targeted medicine) combined with docetaxel (an IV chemotherapy) in people with advanced non-small cell lung cancer (NSCLC) whose tumor has high MET activity. It’s designed to see if this combination can shrink tumors or control the cancer after the first standard treatment.
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
Hear when a new Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.